228 related articles for article (PubMed ID: 31456520)
1. Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutations in the Occurrence and Treatment of Pancreatic Cancer.
Zhu Z; Xiao S; Hao H; Hou Q; Fu X
Curr Top Med Chem; 2019; 19(23):2176-2186. PubMed ID: 31456520
[TBL] [Abstract][Full Text] [Related]
2. Critical role of oncogenic KRAS in pancreatic cancer (Review).
Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
[TBL] [Abstract][Full Text] [Related]
3. Targeting KRAS in pancreatic cancer.
Stickler S; Rath B; Hamilton G
Oncol Res; 2024; 32(5):799-805. PubMed ID: 38686056
[TBL] [Abstract][Full Text] [Related]
4. KRAS-related proteins in pancreatic cancer.
Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
[TBL] [Abstract][Full Text] [Related]
5. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
6. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
7. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
[TBL] [Abstract][Full Text] [Related]
8. Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies.
Khan S; Budamagunta V; Zhou D
Adv Cancer Res; 2023; 159():145-184. PubMed ID: 37268395
[TBL] [Abstract][Full Text] [Related]
9. Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells.
Fitzgerald TL; Lertpiriyapong K; Cocco L; Martelli AM; Libra M; Candido S; Montalto G; Cervello M; Steelman L; Abrams SL; McCubrey JA
Adv Biol Regul; 2015 Sep; 59():65-81. PubMed ID: 26257206
[TBL] [Abstract][Full Text] [Related]
10. Targeting KRAS in pancreatic cancer: new drugs on the horizon.
Bannoura SF; Uddin MH; Nagasaka M; Fazili F; Al-Hallak MN; Philip PA; El-Rayes B; Azmi AS
Cancer Metastasis Rev; 2021 Sep; 40(3):819-835. PubMed ID: 34499267
[TBL] [Abstract][Full Text] [Related]
11. Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy.
Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL
J Cell Physiol; 2019 May; 234(5):5601-5612. PubMed ID: 30341899
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma.
Hashimoto D; Arima K; Yokoyama N; Chikamoto A; Taki K; Inoue R; Kaida T; Higashi T; Nitta H; Ohmuraya M; Hirota M; Beppu T; Baba H
Pancreas; 2016 Sep; 45(8):1111-4. PubMed ID: 26967456
[TBL] [Abstract][Full Text] [Related]
13. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
14. Porphyrins to restrict progression of pancreatic cancer by stabilizing KRAS G-quadruplex: In silico, in vitro and in vivo validation of anticancer strategy.
Pattanayak R; Barua A; Das A; Chatterjee T; Pathak A; Choudhury P; Sen S; Saha P; Bhattacharyya M
Eur J Pharm Sci; 2018 Dec; 125():39-53. PubMed ID: 30223034
[TBL] [Abstract][Full Text] [Related]
15. KRAS: A Promising Therapeutic Target for Cancer Treatment.
Wu HZ; Xiao JQ; Xiao SS; Cheng Y
Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
[TBL] [Abstract][Full Text] [Related]
16. Repositioning of Montelukast to inhibit proliferation of mutated KRAS pancreatic cancer through a novel mechanism that interfere the binding between KRAS and GTP/GDP.
Xia Y; Zhang S; Luo H; Wang Y; Jiang Y; Jiang J; Yuan S
Eur J Pharmacol; 2023 Dec; 961():176157. PubMed ID: 37939992
[TBL] [Abstract][Full Text] [Related]
17. Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer.
Bahrami A; Hassanian SM; ShahidSales S; Farjami Z; Hasanzadeh M; Anvari K; Aledavood A; Maftouh M; Ferns GA; Khazaei M; Avan A
J Cell Physiol; 2018 Mar; 233(3):2058-2066. PubMed ID: 28262927
[TBL] [Abstract][Full Text] [Related]
18. Intraductal papillary mucinous neoplasms of the pancreas: Clinical association with KRAS.
Chang XY; Wu Y; Li Y; Wang J; Chen J
Mol Med Rep; 2018 Jun; 17(6):8061-8068. PubMed ID: 29658583
[TBL] [Abstract][Full Text] [Related]
19. A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth.
Pan T; Zhang Y; Zhou N; He X; Chen C; Liang L; Duan X; Lin Y; Wu K; Zhang H
Oncotarget; 2016 Jul; 7(28):44299-44309. PubMed ID: 27322423
[TBL] [Abstract][Full Text] [Related]
20. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
